Overview Pembro+Chemo in Brain Mets Status: Not yet recruiting Trial end date: 2033-05-01 Target enrollment: Participant gender: Summary The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis. Phase: Phase 2 Details Lead Sponsor: John L. Villano, MD, PhDTreatments: Albumin-Bound PaclitaxelCarboplatinPaclitaxelPembrolizumabPemetrexed